Clinical trial NCT00467610 - References

Myelodysplastic Syndrome — Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS

Citation(s)

•   Aul C, Germing U, Gattermann N, Minning H
  Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res. 1998 Jan;22(1):93-100.
•   Aul C, Giagounidis A, Germing U
  Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001 Jun;73(4):405-10. Review.
•   Catenacci DV, Schiller GJ
  Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005 Nov;19(6):301-19. Review.
•   Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL; World Health Organization(WHO) international working group
  Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 1;96(12):3671-4.
•   Dhar GJ, Bossenmaier I, Cardinal R, Petryka ZJ, Watson CJ
  Transitory renal failure following rapid administration of a relatively large amount of hematin in a patient with acute intermittent porphyria in clinical remission. Acta Med Scand. 1978;203(5):437-43.
•   Fibach E, Kollia P, Schechter AN, Noguchi CT, Rodgers GP
  Hemin-induced acceleration of hemoglobin production in immature cultured erythroid cells: preferential enhancement of fetal hemoglobin. Blood. 1995 May 15;85(10):2967-74.
•   Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J
  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079-88. Erratum in: Blood 1998 Feb 1;91(3):1100.
•   Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Björk J, Strömberg U, Nilsson PG, Mitelman F, Hagmar L, Johansson B
  Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia. 2002 Dec;16(12):2366-78.
•   McHale CM, Winter PC, Lappin TR
  Erythroid gene expression is differentially regulated by erythropoietin, haemin and delta-aminolaevulinic acid in UT-7 cells. Br J Haematol. 1999 Mar;104(4):829-37.
•   Monette FC, Holden SA
  Hemin enhances the in vitro growth of primitive erythroid progenitor cells. Blood. 1982 Aug;60(2):527-30.
•   Porter PN, Meints RH, Mesner K
  Enhancement of erythroid colony growth in culture by hemin. Exp Hematol. 1979 Jan;7(1):11-6.
•   Rund D, Ben-Yehuda D
  Therapy-related leukemia and myelodysplasia: evolving concepts of pathogenesis and treatment. Hematology. 2004 Jun;9(3):179-87. Review.
•   Thompson JE, Luger SM
  The role of hematopoietic stem cell transplantation in myelodysplastic syndrome. Oncology (Williston Park). 2005 Apr;19(4):533-42; discussion 542-4, 547-8. Review.
•   Timonen TT, Kauma H
  Therapeutic effect of heme arginate in myelodysplastic syndromes. Eur J Haematol. 1992 Nov;49(5):234-8.
•   Vidaza® Product Prescribing Information
  Pharmion Corporation, 5-18-04 Edition
•   Volin L, Ruutu T, Knuutila S, Tenhunen R
  Heme arginate treatment for myelodysplastic syndromes. Leuk Res. 1988;12(5):423-31.
•   Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG
  Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994 Aug;87(4):743-5.

A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

Details for clinical trial NCT00467610